The alliance will join Sanofi's oncology pipeline with MD Anderson's premier clinical trials infrastructure to identify new biomarkers and streamline patient selection.
The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.
The studies highlighted the activity of three drugs in NSCLC patients characterized by HER2 mutations, CECAM5 overexpression, and high PD-L1 expression.
The data from the trial will support regulatory submissions in the US and EU for Libtayo as a first-line option for PD-L1 positive non-small cell lung cancer patients.
